Asundexian clinical trials
Also written BAY2433334.
How each study uses asundexian is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses asundexian is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini StrokeCompletedPhase 3BayerNCT05686070Written as Asundexian (BAY2433334)How we know
- A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for StrokeTerminatedPhase 3BayerNCT05643573Written as Asundexian (BAY2433334)How we know
- A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver FunctionCompletedPhase 1BayerNCT05419635Written as Asundexian (BAY2433334)How we know
- Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.CompletedPhase 2BayerNCT04304508Written as BAY2433334How we know
- Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart AttackCompletedPhase 2BayerNCT04304534Written as BAY2433334How we know
- Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.CompletedPhase 2BayerNCT04218266Written as BAY2433334How we know
What changed recently
From the registry's own updates since Oct 22, 2026.
Codes
What other systems call asundexian · ClinicalTrials.gg INT002077
- UNII (FDA) LA585UM8DEASUNDEXIANConfirmed FDA, Wikidata
- Wikidata Q123534093asundexianConfirmed FDA, Wikidata
- NCI Thesaurus C175744AsundexianOne source FDA
- DrugBank DB19088One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LA585UM8DE | ASUNDEXIAN | Confirmed FDA, Wikidata |
| Wikidata | Q123534093 | asundexian | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175744 | Asundexian | One source FDA |
| DrugBank | DB19088 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.